preclinical « Science and Enterprise

National Science Foundation is funding a new system that uses artificial intelligence to find optimal combinations… https://t.co/jbZAJqQpmT
about 20 hours ago
New post on Science and Enterprise: NSF Funds AI Covid-19 Drug Combo Simulation https://t.co/j7DsIncCUk #Science #Business
about 20 hours ago
A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for… https://t.co/CVwEr6dEoU
about 20 hours ago
New post on Science and Enterprise: Gene-Edited Transplant Organ Company Raises $125M https://t.co/UYlUcA8Z5X #Science #Business
about 1 day ago
A home Covid-19 test is being evaluated with a smartphone app, as part of an NIH program to quickly develop Covid-1… https://t.co/82gYsU3rvr
about 2 days ago

Gene-Edited Transplant Organ Company Raises $125M

By Alan, on March 2nd, 2021%

A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for human transplantation. . . . → Read More: Gene-Edited Transplant Organ Company Raises $125M

AI Process Discovers, Tests Fibrosis Drug in 18 Months

By Alan, on February 25th, 2021%

A provider of drug discovery services based on artificial intelligence says in 18 months it identified and tested in mice a new drug for a chronic lung disease. . . . → Read More: AI Process Discovers, Tests Fibrosis Drug in 18 Months

FDA Issues Covid-19 Variant Regulatory Guidance

By Alan, on February 22nd, 2021%

Food and Drug Administration is updating its regulatory guidance for Covid-19 drugs and diagnostics to cover emerging mutations in the SARS-CoV-2 virus. . . . → Read More: FDA Issues Covid-19 Variant Regulatory Guidance

Engineered Cell Therapy Company Issues $588M IPO

By Alan, on February 4th, 2021%

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

Cancer Immunotherapy Adapted for HIV

By Alan, on February 1st, 2021%

A biotechnology company is adapting and licensing its immunotherapy process, originally designed for cancer, as a cure for HIV infections. . . . → Read More: Cancer Immunotherapy Adapted for HIV

Covid-19 Vaccine Shown Active Against Variants

By Alan, on January 25th, 2021%

Moderna Inc., developer of a vaccine to prevent Covid-19 disease, says lab test results show antibodies from the vaccine neutralize two recently found viral mutations. . . . → Read More: Covid-19 Vaccine Shown Active Against Variants

Multi-Variant Covid-19 Vaccine in the Works

By Alan, on January 19th, 2021%

A vaccine protecting against multiple Covid-19 viral variations is in development, with an early-stage clinical trial expected to begin soon. . . . → Read More: Multi-Variant Covid-19 Vaccine in the Works

Biotech Licenses mRNA Technology for Aging

By Alan, on January 13th, 2021%

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Vaccine Shown Active Against New Covid-19 Variants

By Alan, on January 8th, 2021%

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

Synthetic Virus Company Forms, Raises $77M

By Alan, on January 5th, 2021%

A new biotechnology enterprise is underway that develops synthetic viruses attacking solid tumor cancers, based on research at the Salk Institute. . . . → Read More: Synthetic Virus Company Forms, Raises $77M

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise